Instead, reductions in cardiovascular disease and chronic kidney disease are now, through new and effective treatment options, priority treatment objectives.1 Two classes of drugs, sodium glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, provide cardiovascular and kidney benefits, particularly in patients with established cardiovascular or kidney disease,2 with trustworthy guidelines providing recommendations stratified by baseline risks.2, 3. The gene discussed is SLC5A2; the disease is kidney disorder.